Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Raptiva · 4 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Raptiva (efalizumab) | DRUG | - |
Inclusion Criteria: * Signed informed consent * Previous participation in Study ACD2600g * For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study Exclusion Criteria: * Any medical condition that, in the judgment of the investigato...
Raptiva is an investigational small molecule being developed for the treatment of psoriasis, specifically plaque psoriasis, in the dermatology therapeutic area. It is being studied in adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Raptiva is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the safety and efficacy of Raptiva in patients with psoriasis and plaque psoriasis.
Raptiva is in Phase 1 clinical development. While some completed trials were Phase 3, the current development stage is Phase 1, and it remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation.
Raptiva has been studied in three completed trials: NCT00096603, NCT00109252, and NCT00109317, all in Phase 3 for psoriasis. Additionally, NCT00382512 is a Phase 1 trial in plaque psoriasis. All trials are completed, with a total enrollment of 1,136 participants.
Yes, Raptiva is also known as efalizumab. One of its clinical trials, NCT00382512, specifically evaluates the effects of efalizumab on immune responses in subjects with moderate plaque psoriasis, confirming that Raptiva and efalizumab refer to the same drug.